The results confirmed a dramatic upregulation of KRT23 in patients with AH (n = 51) compared with normal livers (n = 7) and other liver diseases including compensated cirrhosis (n = 10), hepatitis C (n = 10, HCV) and NASH (n = 14), (P < 0.001) (Fig. 3a). Here, KRT23 is linked to metabolic dysfunction-associated steatohepatitis.